UroGen Pharma Ltd. 4

Chief Medical Officer Mark Schoenberg sold 60,677 URGN ordinary shares for about $2.85 million.

On August 20, 2026, UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 60,677 ordinary shares of URGN at a weighted average price of $47.05 per share, in multiple transactions executed within a price range of $46.30 to $49.70. Following this disposition, his direct ownership decreased to 59,086 ordinary shares. Based on the reported sale price as a proxy for current value, the transaction size was approximately $2.85 million, and his remaining holdings are worth roughly $2.78 million.

Filing Facts

CIK

1668243

Ticker

URGN

Form

4

Source Type

fda

Accession

0001437749-26-028840

Alert Tier

7